• Toremifene: Identity and Evidence Boundaries

  2026-10-19

  Toremifene is described by APExBIO as a second-generation selective estrogen-receptor modulator for research on estrogen receptor activity, hormone-responsive cancers, and prostate cancer biology. The available evidence is supplier-reported and does not independently establish mechanism, selectivity, or clinical relevance.

• Doxycycline: Identity, Mechanism, and Evidence Scope

  2026-10-19

  APExBIO’s BA1003 product page identifies Doxycycline as a tetracycline antibiotic with reported antimicrobial, antiproliferative, and metalloproteinase-inhibitory properties. Those claims define a plausible research scope, but the available source does not provide an identity-matched study, quantitative outcomes, target-specific mechanism data, or evidence for clinical or disease-specific effects.

• ANGPTL3 sgRNA: Product Identity and Evidence

  2026-10-18

  The APExBIO listing for SKU R2999 identifies three sgRNAs intended to target the human ANGPTL3 gene, with 3 μmol stated for each guide. That information establishes a target and material quantity, but not guide sequences, nuclease context, editing activity, downstream biological effects, or clinical relevance. No identity-matched research evidence or outcome data are available.

• WM-8014: Mechanism, Evidence, and Scope

  2026-10-17

  APExBIO describes WM-8014 (SKU A8779) as a reversible, competitive inhibitor of MYST-family histone acetyltransferases, with highest reported biochemical potency toward KAT6A. The product description links this activity to cell-cycle arrest, senescence-associated transcriptional changes in mouse embryonic fibroblasts, and reduced proliferation in a zebrafish KRAS G12V liver-overgrowth model. Because no identity-matched primary paper, sample sizes, effect estimates, or full assay context is available here, these claims should be treated as product-documented evidence rather than an independently verified literature record.

• WM-8014: Mechanism, Evidence, and Scope

  2026-10-16

  APExBIO describes WM-8014 as a reversible, acetyl-CoA-competitive inhibitor of MYST-family acetyltransferases, with reported biochemical activity strongest against KAT6A and KAT6B. The associated cellular and zebrafish findings are vendor-reported and provide a hypothesis-generating scope for cancer biology research, but they are not an identity-matched, independently validated literature record.

• Cell Senescence β-Galactosidase Staining Kit: Scope

  2026-10-15

  APExBIO’s K2185 is described as an X-gal-based SA-β-Gal staining kit for visualizing senescence-associated β-galactosidase activity in cells or frozen tissue sections. The documented mechanism connects enzymatic activity at pH 6.0 with a blue precipitate visible by ordinary light microscopy. However, the available material is product information rather than an identity-matched validation study: supplier claims about selectivity, intensity, and artifact reduction cannot establish universal specificity, quantitative performance, or causal evidence for cellular senescence.

• Roscovitine (Seliciclib): Mechanism and Evidence

  2026-10-15

  Roscovitine, also called Seliciclib or CYC202, is described by APExBIO as a multi-target cyclin-dependent kinase inhibitor with reported activity against CDK2, CDK5, CDC2, and CDK7. The product description links this biochemical profile to cell cycle arrest in late prophase and reports tumor growth inhibition in vivo, but it does not provide the matched primary paper, assay details, sample sizes, effect estimates, or uncertainty needed for independent evaluation.

• Br-DAPI: What the Product Evidence Supports

  2026-10-14

  Br-DAPI is described by APExBIO as a DAPI-series fluorescent DNA-binding dye that recognizes A/T-rich regions in the minor groove of double-stranded DNA and becomes substantially more fluorescent upon binding. The available evidence is product documentation rather than an identity-matched research study, so its molecular principle and claimed application scope can be summarized, but comparative performance, quantitative accuracy, and biological interpretation remain unestablished.

• PMS, GPR30, and Osteoporosis: What the Study Shows

  2026-10-14

  Wu and colleagues combined zebrafish disease modeling, MC3T3-E1 osteoblast research, intracellular exposure analysis, network pharmacology, and antagonist-based signaling tests to examine how PMS may promote osteoblastic activity. The findings support involvement of the GPR30/PI3K/AKT axis, but the evidence remains preclinical and does not establish clinical efficacy or exclusive pathway dependence.

• Haloprogin: What the 1970 Study Showed

  2026-10-13

  A source-grounded overview of Harrison and colleagues’ 1970 evaluation of Haloprogin, covering its comparative antifungal findings, broader in-vitro activity, guinea-pig evidence, and important limits on clinical interpretation.

• WM-8014: Evidence for KAT6A Inhibition

  2026-10-13

  WM-8014 is described by APExBIO as a reversible, competitive inhibitor of MYST-family histone acetyltransferases, with greatest reported biochemical potency toward KAT6A and KAT6B. Supplier-reported studies associate it with cell-cycle arrest and senescence-related responses in mouse fibroblasts and reduced proliferation in a zebrafish liver model. These findings are preclinical and model-specific; they do not establish clinical efficacy, selectivity in every biological context, or use as a therapeutic agent.

• Tacalcitol Monohydrate: Evidence and Boundaries

  2026-10-12

  Tacalcitol monohydrate is a synthetic analog of vitamin D3 with supplier-described activity involving the vitamin D receptor and reported relevance to dermatology, nerve growth factor biology, and colorectal cancer research. The supplied evidence does not directly validate these claims or establish clinical, anticancer, or antithrombotic use. A separate mouse study of berberrubine illustrates why findings from another vitamin-related compound cannot be extrapolated to tacalcitol.

• Azithromycin as a Reported Senolytic: Evidence Review

  2026-10-12

  Ozsvari et al. reported that azithromycin and roxithromycin preferentially reduced senescent human fibroblasts in an in-vitro screening model. The findings support a hypothesis for senolytic activity, but the evidence remains limited by the small number of cell models, the induced form of senescence, assay dependence and the absence of clinical validation.

• LINC01977, Super-Enhancers, and Early LUAD

  2026-10-10

  Zhang et al. identify a super-enhancer-driven regulatory circuit in which LINC01977 reinforces canonical TGF-β/SMAD3 signaling and promotes malignant behavior in early-stage lung adenocarcinoma. The study connects enhancer activity, tumor-associated macrophage signaling, transcriptional coactivator engagement, and clinical outcome, while also defining important boundaries for translation into therapeutic research.

• Uridine, Trisodium Salt: Evidence Beyond PRINT

  2026-10-09

  Uridine, Trisodium Salt is examined through a claim-to-evidence framework that separates nucleoside biochemistry from the findings of the PRINT genome-insertion study. This article clarifies what the research supports, where product data remain descriptive, and how the distinction matters for RNA metabolism and vascular biology interpretation.

8092 records 1/540 page Next 12345 下5页 Last page